Abstract
This is a retrospective study documenting the use of tenecteplase in 41 cases of suspected or confirmed pulmonary embolism receiving in-hospital tenecteplase as per weight-adjusted dosing in addition to standard heparin and oral anticoagulant therapy. The presenting symptoms of dyspnoea, chest pain, hemoptysis and syncope were found in 40 (97.56%), 19 (46.34%), 6 (14.63%) and 9 (21.95%) patients, respectively. There was one case of mortality who was a 26 yrs old female of postpartum pulmonary thrombo-embolism with severe hypotension, cyanosis, bilateral crepitations in lungs and pulmonary hypertension. In the 40 survived patients, there was alleviation of dyspnoea and hemoptysis in all patients. Significant reduction in tachycardia (P < 0.0001) and increase in the oxygen saturation (SaO2) (P < 0.0001) were seen at discharge as compared to at the time of presentation. Eighteen patients had hypotension which recovered in all patients till the time of discharge (P < 0.0001). There was a significant reduction in right ventricular systolic pressure in all 18 patients who underwent 2-D echocardiography both before and after the tenecteplase therapy. Resolution of pulmonary embolism on CT pulmonary angiography was documented in only two patients. No bleeding events or any other adverse events were reported during this study. The present study suggests favourable efficacy of tenecteplase in patients with suspected or confirmed acute pulmonary embolism. Although no major adverse events were noted, a large prospective study on the use of tenecteplase in pulmonary embolism is suggested.
References
Kasper W, Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser KD et al (1997) Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 30:1165–1171
Loebinger MR, Bradley JC (2004) Thrombolysis in pulmonary embolism: are we unerusing it? Q J Med 97:361–365. doi:10.1093/qjmed/hch069
Dong BR, Hao Q, Yue J, Wu T, Liu GJ (2009) Thrombolytic therapy for pulmonary embolism. Cochrane database of systematic reviews issue 3. Art. No.: CD004437. doi:10.1002/14651858.CD004437.pub3
Dalen JE (2002) Pulmonary embolism: what have we learned since virchow? Treatement and prevention. Chest 122:1801–1817. doi:10.1378/chest.122.5.1801
Melandri G, Vagnarelli F, Calabrese D, Semprini F, Nanni S, Branzi A (2009) Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manage 5:249–325
Kline JA, Hernandez-Nino J, Jones AE (2007) Tenecteplase to treat pulmonary embolism in the emergency department. J Thromb Thrombolysis 23:101–105. doi:10.1007/s11239-006-9018-3
Pathak L, Patil S, Parikh AP, Seth SA (2010) Tenecteplase in acute pulmonary embolism. Indian Heart J 62:342–343
Prescribing Information: Elaxim. Gennova Biopharmaceuticals Ltd, India. Downloaded from http://www.elaxim.co.in/brochure.pdf on 31 Aug 2010
Wells PS, Anderson DR, Rodger M, Ginsberg JS, Kearon C, Gent M, Turpie AG, Bormanis J, Weitz J, Chamberlain M, Bowie D, Barnes D, Hirsh J (2000) Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 83(3):416–420
Guidelines on the diagnosis, management of acute pulmonary embolism (2008) Eur Heart J 29:2276–2315. doi:10.1093/eurheartj/ehn310
Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W (2002) Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 347:1143–1150
Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE (2004) Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3):401S–408S
Carson JL, Kelley MA, Duff A et al (1992) The clinical course of pulmonary embolism. N Engl J Med 326:1240–1245
Stein PD, Hull RD, Raskob G (1994) Risks for major bleeding from thrombolytic therapy in patients with acute pulmonary embolism. Consideration of noninvasive management. Ann Intern Med 121(5):313–317
Sinnaeve PA, Alexander JB, Belmans AC et al (2003) One-year follow-up of the ASSENT-2 trial: A double-blind, randomized comparison of single bolus tenecteplase and front-loaded alteplase in 16, 949 patients with ST elevation acute myocardial infarction. Am Heart J 146:27–32. doi:10.1016/S0002-8703(03)00117-0
Becattini C, Agnelli G, Salvi A, Grifoni S, Pancaldi LG, Enea I et al (2010) Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res 125:e82–e86. doi:10.1016/j.thromres.2009.09.017
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bhuvaneswaran, J.S., Premchand, R.K., Iyengar, S.S. et al. Tenecteplase in the treatment of acute pulmonary thrombo-embolism. J Thromb Thrombolysis 31, 445–448 (2011). https://doi.org/10.1007/s11239-010-0524-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-010-0524-y